STAT

Everyone agrees this superbug is a threat. Few are willing to fund research to stop it

Everyone agrees the superbug is a threat to human health. Few are willing to fund research stop it.
Candida auris

In the universe of scary drug-resistant pathogens that can kill, Candida auris is having a moment. The freaky fungus, which is behaving in ways scientists didn’t think fungi could act, has been garnering headlines because of its uncanny ability to resist multiple antifungal drugs and settle into hospital rooms so persistently it can take renovations to get rid of it.

But while concern about the superbug has grown exponentially in recent years, funding for research to stop it has not. Scientists who work in mycology — the study of fungi — say there is precious little money available to study Candida auris.

“Traditionally, mycology has been the ugly duckling of infectious diseases,” said Dr. Luis Ostrosky, professor of infectious diseases at McGovern Medical School at the University of Texas Health Science Center

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

Related Books & Audiobooks